BACKGROUND: Dyslipidaemia is more frequent in solid organ transplant recipients than in the general population. In order to reduce the overall cardiovascular risk in transplant patients lipid-lowering drugs, especially statins, have become widely used. However, the use of statins in transplant recipients taking cyclosporine A (CsA) results in significantly increased risk for statin induced side-effects ...